Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective, Observational Study On The Efficacy And Safety Of Lorlatinib In ALK or ROS1 Metastatic Non-Small Cell Lung Cancer Patients Treated Within The Compassionate Use Program In Spain

NCT05167500 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT05167500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05167500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective, Observational Study On The Efficacy And Safety Of Lorlatinib In ALK or ROS1 Metastatic Non-Small Cell Lung Cancer Patients Treated Within The Compassionate Use Program In Spain
Lead sponsor
Fundación GECP
Phase
Observational
Overall status
Completed
Start date
December 9, 2021
Completion date
December 30, 2022
Enrollment
118 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non small cell lung cancer